Cargando…

Obinutuzumab-Induced B Cell Depletion Reduces Spinal Cord Pathology in a CD20 Double Transgenic Mouse Model of Multiple Sclerosis

B cell-depleting therapies have recently proven to be clinically highly successful in the treatment of multiple sclerosis (MS). This study aimed to determine the effects of the novel type II anti-human CD20 (huCD20) monoclonal antibody (mAb) obinutuzumab (OBZ) on spinal cord degeneration in a B cell...

Descripción completa

Detalles Bibliográficos
Autores principales:	Breakell, Thomas, Tacke, Sabine, Schropp, Verena, Zetterberg, Henrik, Blennow, Kaj, Urich, Eduard, Kuerten, Stefanie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7559311/ https://www.ncbi.nlm.nih.gov/pubmed/32962135 http://dx.doi.org/10.3390/ijms21186864

Ejemplares similares

Effects of a Fully Humanized Type II Anti-CD20 Monoclonal Antibody on Peripheral and CNS B Cells in a Transgenic Mouse Model of Multiple Sclerosis
por: Tacke, Sabine, et al.
Publicado: (2022)

The presence of cerebellar B cell aggregates is associated with a specific chemokine profile in the cerebrospinal fluid in a mouse model of multiple sclerosis
por: Schropp, Verena, et al.
Publicado: (2023)

B Cells in Multiple Sclerosis and Virus-Induced Neuroinflammation
por: Chunder, Rittika, et al.
Publicado: (2020)

Obinutuzumab: B-cell depletion: case report
Publicado: (2021)

Identification of a novel role for matrix metalloproteinase-3 in the modulation of B cell responses in multiple sclerosis
por: Chunder, Rittika, et al.
Publicado: (2022)

Contribution of LTi and T(H)17 cells to B cell aggregate formation in the central nervous system in a mouse model of multiple sclerosis
por: Schropp, Verena, et al.
Publicado: (2019)

A Dual Role of Osteopontin in Modifying B Cell Responses
por: Chunder, Rittika, et al.
Publicado: (2023)

Nav1.6 promotes inflammation and neuronal degeneration in a mouse model of multiple sclerosis
por: Alrashdi, Barakat, et al.
Publicado: (2019)

Tetramodal Chemical Imaging Delineates the Lipid–Amyloid Peptide Interplay at Single Plaques in Transgenic Alzheimer’s Disease Models
por: Ge, Junyue, et al.
Publicado: (2023)

Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease?
por: Blennow, Kaj, et al.
Publicado: (2010)

The past and the future of Alzheimer's disease CSF biomarkers—a journey toward validated biochemical tests covering the whole spectrum of molecular events
por: Blennow, Kaj, et al.
Publicado: (2015)

The Past and the Future of Alzheimer’s Disease Fluid Biomarkers(1)
por: Blennow, Kaj, et al.
Publicado: (2018)

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
por: Zetterberg, Henrik, et al.
Publicado: (2021)

B-Cell Activity Predicts Response to Glatiramer Acetate and Interferon in Relapsing-Remitting Multiple Sclerosis
por: Tacke, Sabine, et al.
Publicado: (2021)

Disparity in peripheral and renal B-cell depletion with rituximab in systemic lupus erythematosus: an opportunity for obinutuzumab?
por: Reddy, Venkat R, et al.
Publicado: (2021)

Increased intrathecal neurofilament light and immunoglobulin M predict severe disability in relapsing-remitting multiple sclerosis
por: Rosenstein, Igal, et al.
Publicado: (2022)

Intrathecal kappa free light chain synthesis is associated with worse prognosis in relapsing–remitting multiple sclerosis
por: Rosenstein, Igal, et al.
Publicado: (2023)

High levels of kappa free light chain synthesis predict cognitive decline in relapsing-remitting multiple sclerosis
por: Rosenstein, Igal, et al.
Publicado: (2023)

Delineating Amyloid Plaque Associated Neuronal Sphingolipids in Transgenic Alzheimer’s Disease Mice (tgArcSwe) Using MALDI Imaging Mass Spectrometry
por: Kaya, Ibrahim, et al.
Publicado: (2016)

Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease
por: Mattsson, Niklas, et al.
Publicado: (2010)

Cerebrospinal Fluid Analysis Should Be Considered in Patients with Cognitive Problems
por: Zetterberg, Henrik, et al.
Publicado: (2010)

Neuroinflammation Screening in Immunotherapy Trials against Alzheimer's Disease
por: Andreasen, Niels, et al.
Publicado: (2010)

Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders
por: Andreasson, Ulf, et al.
Publicado: (2016)

Differential effects of FTY720 on the B cell compartment in a mouse model of multiple sclerosis
por: Bail, Kathrin, et al.
Publicado: (2017)

No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab
por: Johnsson, Magnus, et al.
Publicado: (2022)

Spitting image: can saliva biomarkers reflect Alzheimer's disease?
por: Ashton, Nicholas J., et al.
Publicado: (2021)

Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis
por: Håkansson, Irene, et al.
Publicado: (2018)

Cerebrospinal fluid growth-associated protein 43 in multiple sclerosis
por: Sandelius, Åsa, et al.
Publicado: (2019)

Obinutuzumab: A Novel Anti-CD20 Monoclonal Antibody for Chronic Lymphocytic Leukemia
por: Evans, Sarah S., et al.
Publicado: (2015)

Biochemical and biophysical characterization of purified native CD20 alone and in complex with rituximab and obinutuzumab
por: Agez, Morgane, et al.
Publicado: (2019)

Obinutuzumab Effectively Depletes Key B-cell Subsets in Blood and Tissue in End-stage Renal Disease Patients
por: Looney, Cary M., et al.
Publicado: (2023)

Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease
por: Zetterberg, Henrik, et al.
Publicado: (2010)

Cerebrospinal fluid biomarkers for Alzheimer disease and subcortical axonal damage in 5,542 clinical samples
por: Skillbäck, Tobias, et al.
Publicado: (2013)

Fluid biomarkers in Alzheimer’s disease – current concepts
por: Rosén, Christoffer, et al.
Publicado: (2013)

Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease
por: Mattsson, Niklas, et al.
Publicado: (2017)

Effects of acute sleep loss on diurnal plasma dynamics of CNS health biomarkers in young men
por: Benedict, Christian, et al.
Publicado: (2020)

Extracellular fluid, cerebrospinal fluid and plasma biomarkers of axonal and neuronal injury following intracerebral hemorrhage
por: Tobieson, Lovisa, et al.
Publicado: (2021)

Axonal injury in asymptomatic individuals preceding onset of multiple sclerosis
por: Jons, Daniel, et al.
Publicado: (2022)

Anti-CD52 antibody treatment depletes B cell aggregates in the central nervous system in a mouse model of multiple sclerosis
por: Simon, Micha, et al.
Publicado: (2018)

Increased midlife triglycerides predict brain β-amyloid and tau pathology 20 years later
por: Nägga, Katarina, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_i5hrc5fnuof3cpk31s6kjqilk5